期刊文献+

肝细胞癌组织中miR-21相关差异表达基因的筛选及其生物学功能的分析

Screening and biological function analysis of differentially expressed genes associated with miR-21 in hepatocellular carcinoma tissue
暂未订购
导出
摘要 目的筛选出肝细胞癌(hepatocellular carcinoma,HCC)组织与正常组织中miR-21相关差异表达基因,并分析其在HCC发生发展中的生物学功能。方法在GEO数据库中选择数据完整性较好的GSE65892数据集,通过GEO2R工具将数据导入R语言,利用limma包筛选出miR-21相关差异表达基因。利用DAVID数据库对miR-21相关差异表达基因进行GO功能和KEGG通路分析。构建miR-21相关差异表达基因的蛋白质-蛋白质互作(PPI)网络,从中筛选出枢纽基因,并通过Kaplan-Meier生存曲线,分析枢纽基因对HCC患者预后预测的价值。结果自GSE65892数据集中共筛选出miR-21相关差异表达基因74个,其中23个基因上调,51个基因下调。GO功能和KEGG通路分析结果显示,这些差异表达基因涉及细胞对脂多糖的反应和血管生成等生物过程。通过PPI网络筛选出18个下调和2个上调的枢纽基因,进一步的生存分析显示,8个枢纽基因(RBM12、HNRNPD、CXCL8、TRA2A、DDIT3、RPS24、LRRC57、CXCL2)与HCC患者的不良预后显著相关。结论RBM12、HNRNPD、CXCL8、TRA2A、DDIT3、RPS24、LRRC57、CXCL2是与患者预后不良显著相关的miR-21相关差异表达的基因,通过参与机体的免疫功能及细胞的分化、增殖及凋亡等生物学过程参与HCC的发生和发展。 Objective To investigate the differentially expressed genes(DEGs)associated with miR-21 between hepatocellular carcinoma(HCC)tissue and normal tissue,as well as their biological function in the development and progression of HCC.Methods The GSE65892 dataset with good data integrity was obtained from the GEO database.GEO2R tool was used to import data into R language,and the limma package was used to identify miR-21-related DEGs.DAVID database was used to perform gene ontology(GO)functional annotation and Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway enrichment analyses of miR-21-related DEGs.A protein-protein interaction(PPI)network was constructed for miR-21-related DEGs to identify hub genes,and the Kaplan-Meier survival curve was used to investigate the value of these hub genes in predicting the prognosis of HCC patients.Results A total of 74 miR-21-related DEGs were identified in the GSE65892 dataset,with 23 upregulated genes and 51 downregulated genes.The GO functional annotation and KEGG pathway enrichment analyses showed that these DEGs were involved in the biological processes such as cellular response to lipopolysaccharide and angiogenesis.The PPI network analysis identified 18 downregulated and 2 upregulated hub genes,and the survival analysis showed that 8 hub genes(RBM12,HNRNPD,CXCL8,TRA2A,DDIT3,RPS24,LRRC57,and CXCL2)were significantly associated with poor prognosis in HCC patients.Conclusion RBM12,HNRNPD,CXCL8,TRA2A,DDIT3,RPS24,LRRC57,and CXCL2 are the miR-21-related DEGs that are significantly associated with poor prognosis of patients.These genes participate in the development and progression of HCC by regulating immune function and cell differentiation,proliferation,and apoptosis.
作者 孙诚攻 田瑛 姜枫 SUN Chenggong;TIAN Ying;JIANG Feng(The Affiliated Traditional Chinese Medicine School of Guangxi University of Chinese Medicine,Nanning 530015,China)
出处 《精准医学杂志》 2026年第1期72-75,82,共5页 Journal of Precision Medicine
基金 全国中医药创新骨干人才培训项目(国中医药办人教函[2019]91号) 广西一流学科建设项目重点课题(2018XK088) 广西第二批广西医学高层次骨干人才培养“139”计划项目(桂卫科教发[2018]22号) 广西中医药大学附属瑞康医院中医名医工程项目(院字[2019]41号)。
关键词 肝肿瘤 数据库 遗传学 核糖体蛋白质类 微RNAS 基因表达 Liver neoplasms Databases genetic Ribosomal proteins MicroRNAs Gene expression
  • 相关文献

参考文献2

二级参考文献192

  • 1Jian-Yong Lei,Wen-Tao Wang,Lu-Nan Yan.“Metroticket” predictor for assessing liver transplantation to treat hepatocellular carcinoma:A single-center analysis in China's Mainland[J].World Journal of Gastroenterology,2013,19(44):8093-8098. 被引量:5
  • 2F. Y.Yao,L.Xiao,N. M.Bass,R.Kerlan,N. L.Ascher,J. P.Roberts.Liver Transplantation for Hepatocellular Carcinoma: Validation of the UCSF‐Expanded Criteria Based on Preoperative Imaging[J].American Journal of Transplantation.2007(11)
  • 3Pierre-Alain Clavien,Mickael Lesurtel,Patrick MM Bossuyt,Gregory J Gores,Bernard Langer,Arnaud Perrier.Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J]. Lancet Oncology . 2012 (1)
  • 4Josep M. Llovet,Jordi Bruix.Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival[J]. Hepatology . 2003 (2)
  • 5Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J].Lancet Oncology.2009(1)
  • 6European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma[J].Journal of Hepatology.2012(4)
  • 7Riccardo Lencioni,Josep Llovet.Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma[J].Semin Liver Dis.2010(01)
  • 8F.Xavier Bosch,Josepa Ribes,Mireia Díaz,Ramon Cléries.Primary liver cancer: Worldwide incidence and trends[J].Gastroenterology.2004(5)
  • 9Francesca Bravi,Cristina Bosetti,Alessandra Tavani,Silvano Gallus,Carlo La Vecchia.Coffee Reduces Risk for Hepatocellular Carcinoma: An Updated Meta-Analysis[J].Clinical Gastroenterology and Hepatology.2013
  • 10E. Terzi,R. Golfieri,F. Piscaglia,M. Galassi,A. Dazzi,S. Leoni,E. Giampalma,M. Renzulli,L. Bolondi.Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”[J].Journal of Hepatology.2012(6)

共引文献56

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部